Introduction {#S0001}
============

With the progressive aging of the population, Alzheimer's disease (AD), a leading cause of dementia, shows the increasing prevalence and becomes a serious health issue for individuals and society around the world.[@CIT0001] Cognitive deficits of AD depend in part on adult neurogenic damage. As an important structure of the learning and memory system in the brain, dentate gyrus (DG) of the hippocampus can continuously produce new nerve cells.[@CIT0002] The newborn neurons could improve hippocampal-dependent learning and memory, while neurogenesis is blocked in AD patients and animal models that leads to memory loss.[@CIT0003]--[@CIT0006]

The deposition of amyloid-β (Aβ) is considered to be the central link in the pathogenesis of AD.[@CIT0007] Aβ~1-42~ could enhance the RAS/ERK signaling cascade, which implies a pathologic link between Aβ and altered RAS signaling.[@CIT0008] The RAS/RAF/MEK/ERK signaling pathway could transmit extracellular signals into the nucleus to affect cell fate, including cell proliferation, differentiation, survival, and transformation. Activation of this pathway under different conditions could trigger cell specificity and even the opposite response.[@CIT0009] Generally, sustained and well-intensity activation promotes cell proliferation by promoting protein synthesis, cyclin/cyclin-dependent kinase (CDK) complex formation.[@CIT0010] However, overactivation of the pathway blocks the cell cycle and accumulates intracellular cyclinD1, whereas overaccumulation of cyclinD1 binds to the cell cycle inhibitor p21cip1, preventing p21cip1 from degrading, causing cells to enter a resting state.[@CIT0011] Mitogenic overstimulation of neurons led to the dedifferentiation of cells, causing abnormal entry of the cell cycle, ultimately causing neurocyte death.[@CIT0012] In AD, Aβ oligomer-induced abnormal cell cycle activation and subsequent cell loss may be associated with RAS.[@CIT0013] RAS has to be anchored to the inner leaf of the cell membrane through farnesylation to receive and transmit signals.[@CIT0014] The level of RAS farnesylation in the brain of AD patients was significantly higher than that in the elderly with non-cognitive disorders.[@CIT0015] Numerous studies have shown that statins weaken RAS activity by reducing RAS farnesylation, thereby improving cognitive function in AD mice.[@CIT0011],[@CIT0014]

S-trans, trans-farnesylthiosalicylic acid (FTS), a synthetic Ras inhibitor, acts directly on the saturated RAS anchor site in the cell membrane, preventing RAS from binding to these sites.[@CIT0016] The molecular formula of FTS is C~22~H~30~O~2~S 358.54 with molecular weight 493.58 Da, the chemical structure of which is shown in [Figure 1](#F0001){ref-type="fig"}. FTS has been shown to inhibit RAS-dependent cell growth.[@CIT0017] In vitro studies have shown that FTS can organize abnormal cell cycle re-entry induced by soluble Aβ oligomers.[@CIT0013] Recently, a study has shown that the inhibition of RAS by FTS could enhance NMDAr-dependent long-term potentiation by increasing Src activity, resulting in enhanced spatial memory.[@CIT0018] The study focused on the effects of FTS on the survival and neurite outgrowth of Aβ-impaired neonatal neurons and explored its mechanism against AD. Figure 1Chemical structure of FTS.**Abbreviation:** FTS, S-trans, trans-farnesylthiosalicylic.

Materials and Methods {#S0002}
=====================

Aβ~1-42~-Mice as AD Model {#S0002-S2001}
-------------------------

Male mice (ICR, Xuzhou Medical University Animal Experiment Center), aged 3 months, were used in this study. The Aβ~1-42~-mice were obtained as previously described as AD model.[@CIT0019] The experimental programs were approved by the Ethics Committee of Animal Laboratory of Xuzhou Medical University and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Drug Administration {#S0002-S2002}
-------------------

FTS was obtained from Cayman chemical (USA). A daily dose of 5mg/kg of FTS was administered intraperitoneally 4 hrs after Aβ~1-42~ injection. This dose has proven to be both effective and safe for study.[@CIT0017],[@CIT0020]

Morris Water Maze as Behavior Analysis {#S0002-S2003}
--------------------------------------

The test of Morris water maze was performed to assess the ability of spatial memory. In brief, with a pool made of black-colored plastic, the time mice taken to reach the hidden platform was recorded. In addition, the number of mice passing through the platform and the swimming time in the platform quadrant were also scored on all trials.

Immunohistochemistry of 5-Bromo-2-Deoxyuridine and Doublecortin {#S0002-S2004}
---------------------------------------------------------------

All mice received thrice intraperitoneal injection of 5-bromo-2-deoxyuridine (BrdU, Sigma) (50 mg/kg) with an interval of 6 hrs to label newborn cells. On day 1, 14, or 28 after BrdU injection, the sections of brains (40 mm) were obtained from the killed mice using a vibrating microtome. After treated with 0.3% Triton X-100 and 3% normal horse serum for 45 mins, the sections were probed with mouse monoclonal anti-BrdU antibody (1:1000, USA) as the primary antibody at 4 °C overnight. After washed thrice in phosphate buffer saline (PBS), the sections were incubated with biotin-labeled goat anti-mouse IgG antibody as the secondary antibody for 2 hrs. Finally, the sections were washed thrice in PBS and visualized by avidin-biotin horseradish peroxidase complex and 3,3ʹ-diaminobenzidine. Images were captured by an optical microscope (Olympus, Japan) with a 40× objective.

The above same procedure was used for the immunohistochemistry of doublecortin (DCX), in which the primary and secondary antibody was goat polyclonal anti-DCX antibody (USA) and rabbit anti-goat IgG antibody, respectively.

BrdU/Neuronal Nuclei Double Immunofluorescence {#S0002-S2005}
----------------------------------------------

The sections were incubated with rat monoclonal anti-BrdU antibody (UK) and mouse monoclonal anti-neuronal nuclei (NeuN) antibody (USA) and then revealed by CY3-labeled anti-rat IgG antibody (USA) and ﬂuorescein-labeled anti-mouse antibody (USA), respectively. Images were captured by a confocal laser-scanning microscope (Leica, Germany). Quantitative and image analyses refer to the previous description.[@CIT0017]

Nissl Staining {#S0002-S2006}
--------------

Nissl staining is used to detect the nuclei of neurons in fixed, embedded, and frozen tissue. Preparation of brain slices and Nissl staining steps were obtained as previously described.[@CIT0021] Images were captured by an optical microscope (Olympus, Japan). Quantitative and image analyses refer to the previous description.[@CIT0022]

Western Blot {#S0002-S2007}
------------

After the different treatments, the expressions of RAS, ERK, and CREB were detected by Western blot. The entire hippocampus taken quickly from the killed mice was homogenized in a lysis buffer. After centrifuged, the supernatant was collected, and protein concentration was measured with BCA Protein Assay Kit (USA). Total proteins (20 mg) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane. The membrane incubated with RAS, ERK, CREB, or β-actin as primary monoclonal antibodies at 4°C overnight. Subsequently, the membranes were incubated with an HRP-labeled secondary antibody at room temperature for 1 hr. The protein bands were detected using an enhanced chemiluminescence detection system (Millipore).

Statistical Analysis {#S0002-S2008}
--------------------

The data were expressed as the mean ± standard deviation. SPSS 22.0 (SPSS Inc., USA) was performed to analyze the data. Differences among treatments were analyzed by *F*-test. The difference was statistically significant with P \< 0.05.

Results {#S0003}
=======

Improvement of Spatial Cognitive Deficit in Aβ~1-42~- Mice by FTS {#S0003-S2001}
-----------------------------------------------------------------

To assess whether FTS has an impact on the cognitive function, the Morris water maze (MWM) test was used, starting from 2 weeks of the FTS administration. In the visible platform tests used to examine search behavior, the escape latency of each group is similar (P \> 0.05) ([Figure 2A](#F0002){ref-type="fig"}). In the hidden platform tests reflecting hippocampus-dependent spatial memory, compared to the control, Aβ~1-42~-mice took longer to reach the hidden platform on days 4--6 of training (P \< 0.01). But, after the treatment with FTS, Aβ~1-42~-mice improved the escape latency (P \< 0.05), while the control mice were not affected (P \> 0.05) ([Figure 2B](#F0002){ref-type="fig"}). Although the number of Aβ~1-42~-mice passing through the platform and the swimming time in the platform quadrant were significantly less than that of the control mice (P \< 0.01), FTS could correct the reduction in the number of crossings through the platform ([Figure 2C](#F0002){ref-type="fig"}), as well as swimming time in Aβ~1-42~-mice ([Figure 2D](#F0002){ref-type="fig"}). In the entire MWM test, each group of mice has no difference in swimming speed (P \> 0.05) ([Figure 2E](#F0002){ref-type="fig"}). Figure 2FTS improves cognitive deficits in Aβ~1-42~-mice. (**A**) The escape latency of the mice in the Morris water maze test. (**B**) Statistical analysis of the escape latency time. (**C**) The number of crossings through the platform. (**D**) The swimming time in the platform quadrant. (**E**) The swimming speed in the water maze. Data are expressed as mean ± standard deviation, \*P \< 0.05 and \*\*P \< 0.01 vs control mice; \#P \< 0.05 vs Aβ~1-42~-mice.**Abbreviations:** FTS, S-trans, trans-farnesylthiosalicylic; vs, versus.

Neuronal Loss Blocked in Aβ~1-42~-Mice by FTS {#S0003-S2002}
---------------------------------------------

Nissl staining was applied to assess the effects of FTS on Aβ-induced neuronal loss in the hippocampus. The morphological results demonstrated that, compared with control mice, the loss of Nissl bodies, neuron atrophy, and nucleus shrinkage happened in the hippocampal CA1 region of Aβ~1-42~-mice, and the neurons disappeared ([Figure 3A](#F0003){ref-type="fig"}). Further quantification indicated that neurons in the hippocampal CA1 area of the Aβ~1-42~-mice decreased on the first day (P \< 0.05), and the difference was more obvious at 14 days (P \< 0.01) and reached the maximum at 28 days (P \< 0.01). But, Aβ-induced hippocampal neuron loss in Aβ~1-42~-mice could be blocked by FTS (P \< 0.01), while control mice were not affected (P \> 0.05) ([Figure 3B](#F0003){ref-type="fig"}) Figure 3Effect of FTS on neuronal loss in hippocampal CA1 region of Aβ~1-42~-mice. (**A**) Typical morphology of Nissl staining across hippocampal CA1 region (magniﬁcation 400×, scale bar 50 µm). (**B**) Quantiﬁcation of Nissl bodies (\#p \< 0.05, \#\#p \< 0.01 vs control mice, +p \< 0.05, ++p \< 0.01 vs Aβ~1-42~-mice).**Abbreviations:** FTS, S-trans, trans-farnesylthiosalicylic; vs, versus.

Protection Survival of Newborn Neurons in Aβ~1-42~-Mice by FTS {#S0003-S2003}
--------------------------------------------------------------

Although Aβ~1-42~ injection stimulates cell proliferation, regrettably, half of the newborn neurons die within 2 weeks.[@CIT0023] In this study, newborn cells were labeled by intraperitoneal injection of BrdU to examine the effect of FTS on their survival and maturation impaired from Aβ~1-42~, in which BrdU-positive (BrdU ^+^) cells were counted on days 1, 14, and 28, respectively. Compared with the control mice, the number of 1-day-old BrdU^+^ cells in Aβ~1-42~-mice was increased (P \< 0.05) ([Figure 4A](#F0004){ref-type="fig"}). However, compared with the control group, the number of BrdU^+^ cells was significantly reduced in Aβ~1-42~-mice on 14 (P \< 0.01) and 28 days (P \< 0.05), which could be rescued by FTS (P \< 0.05) in a dose-dependent manner with EC~50~ of 3.68 mg/kg (P \< 0.01) ([Figure 4A](#F0004){ref-type="fig"}--[C](#F0004){ref-type="fig"}). By contrast, FTS did not affect the number of 1-day-old, 14-day-old, and 28-day-old BrdU^+^ cells in control mice (P \> 0.05). Similarly, FTS could prevent the loss of 28-day-old BrdU^+^/NeuN^+^ cells in Aβ~1-42~-mice (P \< 0.01) ([Figure 4D](#F0004){ref-type="fig"} and [E](#F0004){ref-type="fig"}). Figure 4The effect of FTS on survival of newborn neurons in Aβ~1-42~-mice. (**A**) Immunohistochemistry of 1-, 14-, and 28-day-old BrdU^+^ cells in control mice (control), FTS-treated control mice (FTS), Aβ~1-42~-mice (Aβ~1-42~), and FTS-treated Aβ~1-42~-mice (Aβ~1-42~/FTS). Scale bar = 50 mm. (**B**) Comparison of the number of 1-day-old BrdU^+^ cells. \#p \< 0.05 and \#\#p \< 0.01 vs control mice; \*p \< 0.05 vs Aβ~1-42~-mice. (**C**) Dose-dependency of FTS-protected 14-day-old BrdU^+^ cells in Aβ~1-42~-mice. \*p \< 0.05 and \*\*P \< 0.01 vs FTS-treated group. (**D**) Immunofluorescence of 28-day-old BrdU^+^/NeuN^+^ cells. Representative pictures of BrdU^+^/NeuN^+^ cells. Scale bar = 25 mm. (**E**) Comparison of the number of 28-day-old BrdU^+^/NeuN^+^ cells. \#\#p \< 0.01 vs control mice; \*\*p \< 0.01 vs Aβ~1-42~-mice.**Abbreviations:** FTS, S-trans, trans-farnesylthiosalicylic; vs, versus; BrdU, 5-bromo-2-deoxyuridine.

Protection of Neurite Growth of Newborn Neurons in Aβ~1-42~-Mice by FTS {#S0003-S2004}
-----------------------------------------------------------------------

DCX is a microtubule-associated protein that is specifically expressed in the soma and dendrites of immature neonatal neurons but not in glial cells.[@CIT0024] As shown in [Figure 5](#F0005){ref-type="fig"}, compared with control mice, not only the number of DCX-positive cells (DCX^+^) (P \< 0.05) and the number of DCX^+^ ﬁbers per DCX^+^ cell (P \< 0.01) was reduced in Aβ~1-42~-mice due to the impairment of Aβ~1-42~. However, FTS could perfectly prevent the decrease in the number of DCX^+^ cells (P \< 0.05) and DCX^+^ ﬁbers (P\<0.01) in Aβ~1-42~-mice. Figure 5Effect of FTS on neurite growth of newborn neurons in Aβ~1-42~-mice. (**A**) Typical image of DCX^+^ cells and ﬁbers in hippocampal DG. Molecular layer (ML) of DG was divided into 3 sub-regions of inner (MLi), middle (MLm), and outer (MLo). GCL indicates granule cell layer. Scale bar =25 mm. (**B**) Comparison of the number of DCX^+^ cells. (**C**) The number of DCX^+^ ﬁbers per DCX^+^ cell. \#P \< 0.05 and \#\#P \< 0.01 vs control mice; \*P \< 0.05 and \*\*P \< 0.01 vs Aβ1-42-mice.**Abbreviations:** FTS, S-trans, trans-farnesylthiosalicylic; vs, versus; DCX, doublecortin; DG, dentate gyrus.

Inhibition of Aβ-Mediated Activation of RAS-ERK Signaling Pathway by FTS {#S0003-S2005}
------------------------------------------------------------------------

Aβ exposure could increase the activation of RAS protein and RAS-ERK signaling cascade activation.[@CIT0008] In the study, compared with DMSO injection mice, the level of hippocampal RAS in Aβ~1-42~-mice was significantly increased on day 1 after Aβ~1-42~ injection (p \< 0.01) ([Figure 6A](#F0006){ref-type="fig"} and [B](#F0006){ref-type="fig"}). The levels of hippocampal ERK phosphorylation (p-ERK) and CREB phosphorylation (p-CREB) were measured on day 13 after Aβ~1-42~ injection. In comparison with controls, the level of p-ERK in Aβ~1-42~-mice increased (P \< 0.01) ([Figure 6C](#F0006){ref-type="fig"} and [D](#F0006){ref-type="fig"}), with a concomitant increase in the level of p-CREB (P \< 0.01) ([Figure 6E](#F0006){ref-type="fig"} and [F](#F0006){ref-type="fig"}). Similar to the decrease in control mice by FTS as RAS inhibitor, the levels of p-ERK and p-CREB in Aβ~1-42~-mice were inhibited (P \< 0.01) ([Figure 6C](#F0006){ref-type="fig"} and [D](#F0006){ref-type="fig"}). Altogether, these findings indicate that FTS could reverse Aβ-induced abnormal activation of ERK signaling pathway in Aβ~1-42~-mice. Figure 6Inhibition of the activation of RAS-ERK signaling pathway in Aβ~1-42~-mice by FTS. (**A**) Western blot analysis of total RAS. β-Actin was used as an internal control. (**B**) Densitometric analysis of RAS. \*\*p \< 0.01 vs DMSO group. (**C**) Western blot analysis of total ERK and p-ERK. (**D**) Densitometric analysis of total ERK and p-ERK. \*\*p \< 0.01; \#\#p \< 0.01 vs control group; ++p \< 0.01 vs Aβ~1-42~. (**E**) Western blot analysis of total CREB and p-CREB. (**F**) Densitometric analysis of total CREB and p-CREB.\*\*p \< 0.01; \#\#p \< 0.01 vs control; ++p \< 0.01 vs Aβ~1-42~.**Abbreviations:** FTS, S-trans, trans-farnesylthiosalicylic; vs, versus; p-ERK, ERK phosphorylation; p-CREB, CREB phosphorylation.

Discussion {#S0004}
==========

In this study, we found that FTS, a RAS inhibitor, could prevent Aβ~1-42~ to impair survival and neurite growth of newborn neurons in hippocampal DG in Aβ~1-42~-mice as an AD model. Behavioral indexes and morphological findings also demonstrated that FTS could improve the learning and spatial memory abilities of Aβ~1-42~-mice. The underlying molecular mechanism should be that FTS inhibited the levels of hippocampal p-ERK and p-CREB activated by Aβ.

The lateral ventricle injection of Aβ~1-42~ oligomer is a mature AD model, which can well reflect the neurotoxicity of Aβ, and is often used in neurogenesis research.[@CIT0022],[@CIT0023],[@CIT0025] It is known that overproduction and subsequent Aβ aggregation limit the survival of new neurons in the DG of APP/PS1 mice.[@CIT0026] In our study, Aβ~1-42~ caused a significant decrease in the number of 14-day-old BrdU^+^ cells which represent newborn neurons[@CIT0027] and DCX^+^ cells which represent early immature neurons[@CIT0028] in hippocampal DG, indicating that many Aβ-induced neoplastic cells were apoptotic within 2 weeks, which is consistent with previous studies.[@CIT0023] However, the number of BrdU^+^ cells in Aβ~1-42~-mice of AD model was significantly increased after 14 days of continuous administration of FTS, compared to that of unadministered AD mice. Furthermore, in Aβ~1-42~-mice, FTS also increased the number of DCX^+^ cells. The above results indicate that FTS not only protects the survival of newborn neurons but also promotes the maturation of neurons. AD is the most common form of age-related dementia and still lacks effective treatments and preventive measures. Most of the therapeutic approaches aimed at reducing Aβ burden fail to improve the clinical symptoms of AD. More and more researchers focus on stimulating neurogenesis and vascularization.[@CIT0029],[@CIT0030] Here, we provided in vivo evidence that the FTS could not only protect the survival of newborn neurons but also promote the maturation in Aβ~1-42~-mice of the AD model. Neonatal neurons integrate into the hippocampal loop after 3--4 weeks of maturation, anatomically supporting the cause--result relationship between neurogenesis and cognitive performance.[@CIT0031] To some extent, neonatal neurons integrate into the hippocampal neural network, replacing the denatured and degenerate nerve cells in AD, thereby improving neuropsychiatric symptoms of learning and spatial memory.[@CIT0032]

A recent study has reported for the first time that the RAS inhibitor, FTS, could improve the spatial memory of AD mice to some extent.[@CIT0018] Consistent with the previous study, our results show that FTS significantly improved spatial learning and memory detected by the MWM test in Aβ~1-42~ mice after 18 days of the treatment with FTS.[@CIT0018] Physical exercise can increase the tolerance of cells and tissues to oxidative stress, vascularization, energy metabolism, and neurotrophin synthesis, which are beneficial for neurogenesis, memory improvement, and brain plasticity.[@CIT0033] A multicenter, investigator-masked, random controlled trial showed that physical exercise improves the physical fitness of AD patients without slowing cognitive impairment in patients with mild-to-moderate dementia.[@CIT0034] A recent study indicated that promoting adult hippocampal neurogenesis could ameliorate AD pathology and cognitive deficits  in the presence of a healthier brain environment stimulated by physical exercise.[@CIT0029] Further investigation of combination pharmacology of FTS and physical exercise based on our present study should be extended to seek a more effective treatment strategy for AD.

Ras is activated by a variety of extracellular stimuli and then activates the RAF--MEK--ERK cytokine kinase cascade and cAMP response element-binding protein (CREB) pathway.[@CIT0014] In APP-expressing B103 neuroblastoma cells, Aβ precursor protein (APP) and Aβ~42~ mediated RAS-MAPK signaling cascade and GSK-3 activation.[@CIT0008] In AD patients, RAS protein and major downstream elements of the MAPK-cascade reaction were elevated at an early stage of the disease.[@CIT0035] Interestingly, the RAS/ERK signaling cascade regulates so many different and even opposite cellular processes; it not only plays a regulatory role in a variety of cellular processes such as proliferation, differentiation, development, learning, survival, etc., but also can cause apoptosis if aberrantly activated.[@CIT0036] Mitogenic overstimulation of neurons is an important cause of abnormal activation of the cell cycle and subsequent cell death,[@CIT0012] which is an important component of the pathogenesis of AD and other degenerative diseases.[@CIT0037] Aβ~42~ oligomer preparation could also induce cell cycle activation and subsequent neuronal loss by activating RAS.[@CIT0013] RAS signaling pathway is involved in synaptic plasticity and memory formation.[@CIT0038] Long-term potentiation (LTP) impairment and learning and memory deficits were observed due to excessive RAS activity in the knock-out mice of Nf1.[@CIT0039] Neural plasticity is considered the neurophysiological correlate of learning and memory. Transcranial magnetic stimulation (TMS) studies have shown that increased cortical excitability and impaired brain plasticity are one of the pathophysiological mechanisms of AD and major depression.[@CIT0040],[@CIT0041] RAS as a small molecule guanosine triphosphate (GTPase) protein needs to be modified by farnesylation to localize on the cell membrane and bind to GTP under the action of guanylate exchange factor (GEF) to activate.[@CIT0042] Aβ could induce phosphorylation of the threonine (668 site) of the cytoplasmic domain of APP, which activates the adaptor protein growth factor receptor-binding protein 2 (Grb2) and then recruits the guanylate exchange factor SOS2, thereby promoting RAS farnesylation.[@CIT0008]

Since RAS activity is associated with neurodegenerative pathways, FTS acts as a chemical RAS inhibitor, which was developed and tested as a cancer drug, and its role in degenerative diseases such as AD has been increasingly studied recently.[@CIT0013],[@CIT0017] Here, we determined that FTS attenuated Aβ-induced ERK, CREB hyperphosphorylation by inhibiting RAS. CREB is an important transcription factor of ERK, and its phosphorylation promotes the transcriptional expression of cyclin-dependent kinases and cyclin genes.[@CIT0043] Mitosis requires ERK activity,[@CIT0044] but if ERK activity in the G2/M phase is too high, it could block mitotic entry and subsequent cell death.[@CIT0045] In our study, RAS in the brain of Aβ~1-42~-mice was significantly higher than that of the control mice, and FTS could inhibit Aβ~1-42~-induced overactivation of the hippocampal ERK signal cascade and CREB. This may be the underlying molecular mechanism of which FTS could protect the survival and neurite growth of newborn neurons and improve spatial cognitive deficits for AD.

Admittedly, our study has some limitations. In the present study, we used mice lateral ventricle injection of Aβ as an AD model, which limits the neurotoxicity of Aβ but not the other pathological features of AD. The effects of adult hippocampal neurogenesis manipulation on tau phosphorylation levels should also be explored in a future study.

Conclusion {#S0005}
==========

In summary, FTS, a synthetic Ras inhibitor, could prevent Aβ~1-42~ to impair survival and neurite growth of newborn neurons in hippocampal dentate gyrus in Aβ~1-42~-mice as the AD model and thus improve the learning and spatial memory via inhibition of RAS/ERK pathway. These findings suggest that FTS could be a potential therapeutic agent for the treatment of AD.
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